# Opening Remarks & Leadership Update

<table>
<thead>
<tr>
<th>Opening Remarks &amp; Leadership Update</th>
<th>Beth Lovette, RN, BSN, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Deputy Director/Section Chief</td>
</tr>
<tr>
<td></td>
<td>Local and Community Support</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Epi Picture</th>
<th>Zack Moore, MD, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>State Epidemiologist and Epidemiology Section Chief</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Policy</th>
<th>Elizabeth Cuervo Tilson, MD, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>State Health Director</td>
</tr>
<tr>
<td></td>
<td>Chief Medical Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vaccine Update</th>
<th>Ryan Jury, RN, MBA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>COVID-19 Vaccine Program Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CCTO Dashboard &amp; Data Quality</th>
<th>Erika Samoff MPH PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>John Young</td>
</tr>
<tr>
<td></td>
<td>COVID-19 Contact Tracing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>K-12 Update</th>
<th>Deborah Porterfield, MD, MPH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Senior Project Director</td>
</tr>
</tbody>
</table>

**QUESTIONS?**  
Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
<th>Role and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Remarks &amp; Leadership Update</td>
<td>Beth Lovette, RN, BSN, MPH</td>
<td>Deputy Director/Section Chief Local and Community Support</td>
</tr>
<tr>
<td>Epi Picture</td>
<td>Zack Moore, MD, MPH</td>
<td>State Epidemiologist and Epidemiology Section Chief</td>
</tr>
<tr>
<td>Policy</td>
<td>Elizabeth Cuervo Tilson, MD, MPH</td>
<td>State Health Director Chief Medical Officer</td>
</tr>
<tr>
<td>Vaccine Update</td>
<td>Ryan Jury, RN, MBA</td>
<td>COVID-19 Vaccine Program Director</td>
</tr>
<tr>
<td>CCTO Dashboard &amp; Data Quality</td>
<td>Erika Samoff MPH PhD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>John Young</td>
<td>COVID-19 Contact Tracing</td>
</tr>
<tr>
<td>K-12 Update</td>
<td>Deborah Porterfield, MD, MPH</td>
<td>Senior Project Director</td>
</tr>
</tbody>
</table>

QUESTIONS?
Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
**Opening Remarks & Leadership Update**

Beth Lovette, RN, BSN, MPH  
Deputy Director/Section Chief  
Local and Community Support

**Epi Picture**

Zack Moore, MD, MPH  
State Epidemiologist and Epidemiology Section Chief

**Policy**

Elizabeth Cuervo Tilson, MD, MPH  
State Health Director  
Chief Medical Officer

**Vaccine Update**

Ryan Jury, RN, MBA  
COVID-19 Vaccine Program Director

**CCTO Dashboard & Data Quality**

Erika Samoff MPH PhD  
John Young  
COVID-19 Contact Tracing

**K-12 Update**

Deborah Porterfield, MD, MPH  
Senior Project Director

---

**QUESTIONS?**

Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
# NORTH CAROLINA LEA FACE MASK POLICIES
(as of 11/5/2021)

![Map of North Carolina showing mask policies](image)

### Masks Optional (O)
- Cabarrus (O)/ Kannapolis (R)
- Sampson (O)/ Clinton (R)

### Masking Mandates

<table>
<thead>
<tr>
<th>Policy</th>
<th>Number of Districts</th>
<th>Percentage of Districts</th>
<th>Number of Students</th>
<th>Percentage of Students</th>
</tr>
</thead>
<tbody>
<tr>
<td>Districts requiring universal face coverings</td>
<td>89</td>
<td>77.39%</td>
<td>1,100,780</td>
<td>82.09%</td>
</tr>
<tr>
<td>Districts making face coverings optional</td>
<td>23</td>
<td>20.00%</td>
<td>233,887</td>
<td>17.44%</td>
</tr>
<tr>
<td>Districts requiring face coverings (partial)</td>
<td>3</td>
<td>2.61%</td>
<td>6,305</td>
<td>0.47%</td>
</tr>
<tr>
<td>Waiting on decision from districts</td>
<td>0</td>
<td>0.00%</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td><strong>Totals</strong></td>
<td><strong>115</strong></td>
<td><strong>100.00%</strong></td>
<td><strong>1,340,972</strong></td>
<td><strong>100.00%</strong></td>
</tr>
</tbody>
</table>

### Vaccination Mandates

<table>
<thead>
<tr>
<th>Policy</th>
<th>Number of Districts</th>
<th>Percentage of Districts</th>
<th>Number of Teachers</th>
<th>Percentage of Teachers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Districts requiring staff to be vaccinated</td>
<td>4</td>
<td>3.48%</td>
<td>5,667</td>
<td>1.90%</td>
</tr>
<tr>
<td>Districts requiring a segment of the student population to be vaccinated</td>
<td>1</td>
<td>0.87%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Notes:
- **O** indicates mask policies are optional.
- **R** indicates mask policies are required.*
# Vaccine Update

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| Opening Remarks & Leadership Update | Beth Lovette, RN, BSN, MPH  
Deputy Director/Section Chief  
Local and Community Support |
| Epi Picture                  | Zack Moore, MD, MPH  
State Epidemiologist and Epidemiology Section Chief |
| Policy                       | Elizabeth Cuervo Tilson, MD, MPH  
State Health Director  
Chief Medical Officer |
| Vaccine Update               | Ryan Jury, RN, MBA  
COVID-19 Vaccine Program Director |
| CCTO Dashboard & Data Quality| Erika Samoff MPH PhD  
John Young  
COVID-19 Contact Tracing |
| K-12 Update                  | Deborah Porterfield, MD, MPH  
Senior Project Director |

QUESTIONS?

Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
### VACCINE APPROVAL OUTLOOK

<table>
<thead>
<tr>
<th></th>
<th>Pfizer</th>
<th>Moderna</th>
<th>Janssen</th>
<th>Pfizer</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOOSTERS</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>BOOSTERS*</td>
<td>✔️</td>
<td>✔️</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOOSTERS</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>5-11</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
</tr>
</tbody>
</table>

| **Which vaccine manufacturers have submitted their packets for review?** |
|--------------------------|-----------------|-----------------|-----------------|
| Pfizer                   | ✔️              | ✔️              | ✔️              | ✔️              |
| Moderna                  | ✔️              | ✔️              |                 |                 |
| Janssen                  | ✔️              |                 | ✔️              |                 |
| Pfizer                   | ✔️              |                 | ✔️              |                 |

| **When will FDA meet to discuss the packets submitted?** |
|--------------------------|-----------------|-----------------|-----------------|
| Pfizer                   | 9/17/21         | 10/14/21        | 10/15/21        | 10/26/21        |
| Moderna                  |                 | 10/21/21        | 10/21/21        |                 |
| Janssen                  |                 |                 | 10/21/21        | 10/29/21        |
| Pfizer                   |                 |                 |                 | 11/3/21         |

<table>
<thead>
<tr>
<th><strong>FDA Emergency Use Authorization</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
</tr>
<tr>
<td>Moderna</td>
</tr>
<tr>
<td>Janssen</td>
</tr>
<tr>
<td>Pfizer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ACIP/CDC Recommendation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
</tr>
<tr>
<td>Moderna</td>
</tr>
<tr>
<td>Janssen</td>
</tr>
<tr>
<td>Pfizer</td>
</tr>
</tbody>
</table>

**Vaccine Preparation Safety Reminder**

- Please refrain from using dispensing pins or vial adapters as COVID-19 vaccines are preservative free and such practices increase the risk of contamination.
- For more information, please see USP’s [FAQ for Optimizing COVID-19 Vaccine Preparation and Safety](https://www.usp.org/).
PFIZER PEDIATRIC VACCINE COMMUNICATIONS TOOLKIT

The NC DHHS: COVID-19 Vaccine Communications Toolkit is live!
The toolkit provides a wide range of resources including flyers, social media graphics, logos, and family vaccine site promotion materials. Please use this toolkit to promote the vaccine among your patients.
The Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have authorized and recommended the Pfizer COVID-19 pediatric vaccines for kids ages 5-11.

Pediatric Vaccine Authorization Tracker
All 3 stages of approval/recommendation have been satisfied and providers may begin administering Pfizer pediatric vaccine to 5-11 year-olds. Requests for pre-orders were completed the week of 10/18.

1. FDA Authorized
2. ACIP Recommended
3. CDC Recommended

Pfizer Pediatric COVID-19 Vaccine Administration Resources
To aid in the administration of these pediatric vaccines, please reference the updated EUA fact sheets, CDC statement and clinical guidance below:
- Updated CDC Clinical Guidance for use of Pfizer-BioNTech COVID-19 Vaccine in children aged 5–11 years
- CDC Statement
- 5-11 Pfizer Fact Sheet for Healthcare Providers
- 5-11 Pfizer Fact Sheet for Recipients and Caregivers
INTERIM PFIZER PEDIATRIC VACCINE ORDERING GUIDANCE

10

Please note: Do not over order. This product has a shelf life of 10-weeks when stored at 2-8C conditions. This is shorter than the shelf life for the adult Pfizer product, so states should plan accordingly. **Overordering increases risk of product expiring.** Order what you need and use what you order.

Sites should evaluate 1st and 2nd dose needs when ordering; second dose should be considered as part of determining initial and follow-on orders for sites. Keep the size of your network manageable. Network should be able to use vaccine within 10 weeks (if stored at 2-8C) and handle **10 doses per vial while minimizing waste.**
PEDIATRIC VACCINE ORDERING GUIDANCE

Additional Guidance

- Pfizer pediatric vaccine requests are now part of the normal vaccine allocation ordering and delivery cadence.

- As of November 9th, more than 100 doses may be ordered in a shipment of 100-dose increments. These shippers should not be used for storage.

- Requests for additional pediatric vaccine will not be considered until 70% of your Pfizer pediatric inventory has been used.

- Moving forward, you will receive weekly pro rata thresholds for pediatric vaccine.

Please click here to access the full ordering One-Pager!
The Pediatric Pfizer EUA only allows 10 doses and thus CDC only recommends 10 doses to be drawn from the pediatric vial.

The Pfizer and federal teams are collecting reports of 11 doses being drawn as they continue to study the vials post manufacturing (similar to what happened with the adult configurations) but an 11th dose is not permissible until/if EUA is amended.
COVID-19 VACCINES NOW AVAILABLE IN NCIR!

COVID-19 vaccine management is available within the North Carolina Immunization Registry (NCIR) in addition to continued availability on the COVID-19 Vaccine Management System (CVMS).

**North Carolina Immunization Registry (NCIR)**

Contains North Carolina’s vaccine administration and inventory records for **all COVID and non-COVID vaccines**, including influenza, HPV, etc.

**COVID-19 Vaccine Management System (CVMS)**

Contains North Carolina’s vaccine administration, account records, and inventory records for **all COVID-19 vaccine** information.

What does this mean for you now?

As a CVMS provider you can continue doing what you already do when it comes to administering and managing COVID-19 vaccines in the CVMS Provider Portal.

Providers currently using NCIR are able to view in NCIR COVID-19 records documented within CVMS.

**Provider System Selection** is available for an organization’s option to use CVMS or NCIR for COVID-19 vaccine management. This option will be visible to all organizations and will be rolled out in phases, starting first with our Vaccines for Children (VFC) providers, who have received specific guidance on this feature. More organizations will be given the option to system select later in 2021/2022.

*Further information to come!*
## CCTO Dashboard & Data Quality

<table>
<thead>
<tr>
<th>Section</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Remarks &amp; Leadership Update</td>
<td>Beth Lovette, RN, BSN, MPH</td>
</tr>
<tr>
<td></td>
<td>Deputy Director/Section Chief</td>
</tr>
<tr>
<td></td>
<td>Local and Community Support</td>
</tr>
<tr>
<td>Epi Picture</td>
<td>Zack Moore, MD, MPH</td>
</tr>
<tr>
<td></td>
<td>State Epidemiologist and Epidemiology Section Chief</td>
</tr>
<tr>
<td>Policy</td>
<td>Elizabeth Cuervo Tilson, MD, MPH</td>
</tr>
<tr>
<td></td>
<td>State Health Director</td>
</tr>
<tr>
<td></td>
<td>Chief Medical Officer</td>
</tr>
<tr>
<td>Vaccine Update</td>
<td>Ryan Jury, RN, MBA</td>
</tr>
<tr>
<td></td>
<td>COVID-19 Vaccine Program Director</td>
</tr>
<tr>
<td>CCTO Dashboard &amp; Data Quality</td>
<td>Erika Samoff MPH PhD</td>
</tr>
<tr>
<td></td>
<td>John Young</td>
</tr>
<tr>
<td></td>
<td>COVID-19 Contact Tracing</td>
</tr>
<tr>
<td>K-12 Update</td>
<td>Deborah Porterfield, MD, MPH</td>
</tr>
<tr>
<td></td>
<td>Senior Project Director</td>
</tr>
</tbody>
</table>

**QUESTIONS?**

Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
CCTO Dashboards

Summary: Dashboards are visual representations of data and key metrics in CCTO. They show a snapshot of all the data in CCTO and are updated throughout the day to maintain accuracy.

Use it for:
- Assessment of contact tracing processes
- Health equity outcomes

Dashboard covers:
1. **COVID-19 Assessment Activity** – breakdown of monitoring events by number of daily assessment records completed
2. **COVID-19 Demographics of Contact or Case Events** – breakdown of demographic data for monitoring events
3. **COVID-19 Outcomes and Activities of Monitoring Events** – breakdown of monitoring events by FMO and digital and phone notifications
4. **COVID-19 Vaccine Referral Activity During Monitoring Events** – breakdown of monitoring events by completion of vaccine referrals

Who has access?
- All CCTO users can access the dashboards
- Data cannot be downloaded but relevant views can be created and exported
- Not available to the public
CCTO Dashboards

Summary: Dashboards are visual representations of data and key metrics in CCTO. They show a snapshot of all the data in CCTO and are updated throughout the day to maintain accuracy.

Use it for:
- Assessment of contact tracing processes
- Health equity outcomes

Dashboard covers:
1. COVID-19 Assessment Activity – breakdown of monitoring events by number of daily assessment records completed
2. COVID-19 Demographics of Contact or Case Events – breakdown of demographic data for monitoring events
3. COVID-19 Outcomes and Activities of Monitoring Events – breakdown of monitoring events by FMO and digital and phone notifications
4. COVID-19 Vaccine Referral Activity During Monitoring Events – breakdown of monitoring events by completion of vaccine referrals

Who has access?
- All CCTO users can access the dashboards
- Data cannot be downloaded but relevant views can be created and exported
- Not available to the public

Contact Monitoring Event Records with Created on Dates Oct 1-14, 2021
CCTO Dashboard Features

Summary: Dashboards are visual representations of data and key metrics in CCTO. They show a snapshot of all the data in CCTO and are updated throughout the day to maintain accuracy.

Dynamic filters, including quick access to only your LHD's data

Dynamic data drill-down capabilities

Trends of monitoring event counts displayable in different timescales, with scrolling
Data Quality Items to Prioritize as Cases Decrease – and we learn from the pandemic

• **Ensure contacts are linked to cases**
  - NC-COVID Event ID of Source Patient for contacts in CCTO
  - Correct Final Monitoring Outcome if contact tests positive/becomes a case in CCTO

• **Track who we reached and exposure setting**
  - Interviewed yes/no in NC COVID, Final Monitoring Outcome in CCTO
  - Risk and exposure data in NC COVID

• **Ensure we have the information to work on disparities in outcomes between demographic groups**
  - Race/ethnicity/gender data in NC COVID and CCTO
  - Select Final Monitoring Outcome and deactivate in CCTO

• **Instructions for NC COVID**
  - [Completing and Reporting Cases with No Follow up to State](PDF)
  - [Reporting Cases to the State/Required Fields in each Package](PDF)
  - Instructions how to update/Report NC COVID Death (PDF)

• **Instructions for CCTO**
  - [Closing Out a Contact Event/Choosing correct FMO](PDF)
  - [Handling Case Patients](PDF)

**LHD staff SharePoint dashboard access**
# K-12 Update

<table>
<thead>
<tr>
<th>Section</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| Opening Remarks & Leadership Update | Beth Lovette, RN, BSN, MPH  
Deputy Director/Section Chief  
Local and Community Support |
| Epi Picture              | Zack Moore, MD, MPH  
State Epidemiologist and Epidemiology Section Chief |
| Policy                   | Elizabeth Cuervo Tilson, MD, MPH  
State Health Director  
Chief Medical Officer |
| Vaccine Update           | Ryan Jury, RN, MBA  
COVID-19 Vaccine Program Director |
| CCTO Dashboard & Data Quality | Erika Samoff MPH PhD  
John Young  
COVID-19 Contact Tracing |
| K-12 Update             | Deborah Porterfield, MD, MPH  
Senior Project Director |

**QUESTIONS?**

Please use the Zoom Q&A function or email your questions to: questionsCOVID19webinar@gmail.com
Staffing support is a program that LEAs and charters can take advantage of in addition to state contracted vendor or independent testing. All public schools that opt-in receive information on how to receive funds in their welcome email.

State Contracted Vendor

- NCDHHS vendor available to support testing program at school/district
- Available to all schools

OR

Independent Testing

- NCDHHS provides free tests that schools may request to perform screening and/or diagnostic testing
- Available to all schools

Staffing Support**

- NCDHHS provides funds for LEAs/charters to hire clinical staff
- Available to LEAs and charters who participate in testing (opt in)

Districts will define their own testing programs or may choose not to participate in testing for 2021-2022. [StrongSchoolsNC K-12 Testing Program Guidance](#)
STRONGSCHOOLSN C K-12 TESTING PROGRAM GOALS

Equitable

Accessible

Minimal disruption

Aligned with guidance

<table>
<thead>
<tr>
<th>Low(^1) Transmission Blue</th>
<th>Moderate Transmission Yellow</th>
<th>Substantial Transmission Orange</th>
<th>High Transmission Red</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students</td>
<td>Do not need to screen</td>
<td>Offer screening testing for students who are not fully vaccinated at least once per week.</td>
<td></td>
</tr>
<tr>
<td>Teachers and staff</td>
<td>Offer screening testing for teachers and staff who are not fully vaccinated at least once per week.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High risk sports and activities</td>
<td>Recommend screening testing for high-risk sports and extracurricular activities(^2) at least once per week for participants who are not fully vaccinated.</td>
<td>Recommend screening 2x per week for participants who are not fully vaccinated.</td>
<td>Cancel or hold virtually to protect in-person learning, unless all participants are fully vaccinated.</td>
</tr>
<tr>
<td>Low-and intermediate-risk sports</td>
<td>Do not need to screen</td>
<td>Recommend screening testing at least 1x per week for participants who are not fully vaccinated.</td>
<td></td>
</tr>
</tbody>
</table>

For more information, please see the StrongSchoolsNC Testing Program Guidance.
<table>
<thead>
<tr>
<th>Populations in Scope</th>
<th>Screening</th>
<th>Diagnostic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students</td>
<td>• Students</td>
<td>• Students</td>
</tr>
<tr>
<td>Staff</td>
<td>• Staff</td>
<td>• Staff</td>
</tr>
<tr>
<td>Teachers</td>
<td>• Teachers</td>
<td>• Teachers</td>
</tr>
<tr>
<td>Athletics and Special Populations</td>
<td>• Athletics and Special Populations</td>
<td>• Athletics and Special Populations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Students and Teachers: 1x week</th>
<th>As needed with presentation of symptoms or known exposure (i.e. close contact)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Athletics and other special pops: 1x week*</td>
<td><strong>Modality will be based on size of population being tested per school per day</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Modality</th>
<th>Pooled PCR testing with Abbott BinaxNOW as the reflex test**</th>
<th>Lab-run PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Abbott BinaxNOW Antigen tests for schools with CLIA waiver and full-time RN oversight</td>
<td></td>
</tr>
</tbody>
</table>

*Benefits of Routine screening: it is a proactive approach to identify asymptomatic cases; it minimizes disruption, and it can be scheduled. Routine screening, with supplemental diagnostic testing, helps get ahead of transmission and be responsive to daily needs. Providing diagnostic tests in-school is a key part of any plan because it helps keep students in school through quick testing results.

*Frequency will vary based on current CDC guidance and the level of community spread. As a baseline, NC DHHS recommends the following, though this can be adjusted over time.**Modality will be based on size of population being tested per school per day.

Both types of testing are important and require parental/guardian consent.
Program Current State – Testing Status as of November 3rd

3,537 total schools in North Carolina

2,329 (66%) schools have opted in (91 LEAs of 115 in NC)

1,875 (81%) schools participating in state vendor program

1,208 (33%) schools have not opted in

453 (19%) schools participating in independent testing

1 Increase of 14 schools from prior week

NC DHHS COVID – 19 Response

Independent survey results show that nearly all are performing diagnostic testing

175 LEAs (1,586 schools)

Stage 1

146 developing their plan

757 are live¹

384 diagnostic +/- screening

176 onboarding for diagnostic, currently screening only

197 screening only

Stage 2

513 are onboarding

17 LEAs (292 schools)

Stage 3

141 have a planned go-live date

19 LEAs (474 schools)

Stage 4

464 are developing their plan

6 LEAs (133 schools)

205 schools in planning stage

248 schools requested 61K antigen tests

10 LEAs (173 schools)

10 LEAs (214 schools)

71 LEAs (1,586 schools)

Including

10 LEAs (214 schools)

Including

Including

513 are onboarding

17 LEAs (292 schools)

Stage 3

19 LEAs (474 schools)

Stage 1

464 are developing their plan

757 are live¹

384 diagnostic +/- screening

176 onboarding for diagnostic, currently screening only

197 screening only

1 Increase of 14 schools from prior week

29 LEAs (687 schools)

23 LEAs (339 schools)

1 LEA (176 schools)

5 LEAs (172 schools)

10 LEAs (173 schools)

10 LEAs (214 schools)

205 schools in planning stage

248 schools requested 61K antigen tests

Independependent s survey results show that nearly all are performing diagnostic testing

including

Including

Including
STRONGSCHOOLSNC K-12 COVID-19 TESTING PROGRAM: SCHOOL DISTRICTS (LEAS) WHO HAVE NOT OPTED IN

25 Total LEAs that have not opted in

- Alexander County Schools
- Allegheny County Schools
- Asheboro City Schools
- Camden County Schools
- Clinton City Schools
- Dare County
- Davidson County
- Edenton-Chowan County Schools
- Franklin County
- Haywood County Schools
- Hyde County Schools
- Lee County Schools
- Mitchell County Schools
- Montgomery County Schools
- Northampton County Schools
- Onslow County Schools
- Person County Schools
- Randolph County School System
- Rockingham County Schools
- Sampson County Schools
- Stokes County Schools
- Thomasville City Schools
- Union County Public Schools
- Wayne County Public Schools
- Yancey County Schools
StrongSchoolsNC K-12 COVID-19 Testing Program: Staff Funding Mechanism

Local and school staffing funds are distributed via 3 mechanisms:

1. NCDHHS ELC ROS → LHD School Liaison
2. NCDHHS ELC ROS → LHD
3. NCDHHS ELC ROS → School Health Staff

Part A. Draft Budget
District/ School submits and can start accruing expenses

Part B. New Contract
Created by DHHS based off draft budget using OPCG template

NC DHHS COVID – 19 Response
StrongSchoolsNC K-12 COVID-19 Testing Program: Staffing Funding

NC DHHS COVID – 19 Response